1
|
Torizuka D, Uto M, Umeda K, Kamitori T, Iwai A, Saida S, Kato I, Mineharu Y, Arakawa Y, Takita J, Mizowaki T. A Scalp Dose Threshold for Preventing Permanent Alopecia in Scalp-Avoidance Whole-Brain Irradiation With Volumetric Modulated Arc Radiation Therapy for Pediatric Patients With Medulloblastomas. Int J Radiat Oncol Biol Phys 2023:S0360-3016(23)00069-X. [PMID: 36708786 DOI: 10.1016/j.ijrobp.2023.01.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2022] [Revised: 12/21/2022] [Accepted: 01/16/2023] [Indexed: 01/27/2023]
Affiliation(s)
| | - Megumi Uto
- Departments of Radiation Oncology and Image-Applied Therapy
| | | | | | | | | | | | - Yohei Mineharu
- Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Yoshiki Arakawa
- Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | | | | |
Collapse
|
2
|
Kessler S, Marzooq A, Sood A, Beebe K, Walsh A, Montoya L, Price H. Alopecia in children undergoing chemotherapy, radiation, and hematopoietic stem cell transplantation: Scoping review and approach to management. Pediatr Dermatol 2022; 39:354-362. [PMID: 35416328 DOI: 10.1111/pde.14995] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/18/2021] [Revised: 03/01/2022] [Accepted: 03/23/2022] [Indexed: 01/07/2023]
Abstract
Alopecia is a common sequela in children undergoing chemotherapy, radiation, and hematopoietic stem cell transplantation. In most cases, this is a transient state in which full hair regrowth eventually occurs, but permanent or persistent alopecia, defined as the presence of incomplete hair regrowth more than 6 months after cessation of treatment, is possible and can be psychologically distressing. We sought to characterize the risk factors that can lead to permanent alopecia following the aforementioned treatments in pediatric populations, as well as diagnostic and treatment options that may be considered, as part of a scoping review of the literature. A general algorithm for approaching these patients was developed based on our findings.
Collapse
Affiliation(s)
- Stephen Kessler
- Division of Dermatology, Phoenix Children's Hospital, Phoenix, Arizona, USA.,Alta Dermatology/Phoenix Dermatology/Kansas City University Medical Center, Kansas City, Missouri, USA
| | - Ali Marzooq
- Division of Dermatology, Phoenix Children's Hospital, Phoenix, Arizona, USA.,Alta Dermatology/Phoenix Dermatology/Kansas City University Medical Center, Kansas City, Missouri, USA
| | - Arun Sood
- Division of Dermatology, Phoenix Children's Hospital, Phoenix, Arizona, USA.,Alta Dermatology/Phoenix Dermatology/Kansas City University Medical Center, Kansas City, Missouri, USA
| | - Kristen Beebe
- Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.,Mayo Clinic Arizona Bone Marrow Transplant Program, Phoenix, Arizona, USA
| | - Alexandra Walsh
- Phoenix Children's Hospital, Center for Cancer and Blood Disorders, Phoenix, Arizona, USA.,The University of Arizona College of Medicine - Phoenix, Phoenix, Arizona, USA
| | - Liliana Montoya
- Division of Dermatology, Phoenix Children's Hospital, Phoenix, Arizona, USA.,The University of Arizona College of Medicine - Phoenix, Phoenix, Arizona, USA
| | - Harper Price
- Division of Dermatology, Phoenix Children's Hospital, Phoenix, Arizona, USA.,The University of Arizona College of Medicine - Phoenix, Phoenix, Arizona, USA
| |
Collapse
|